In this episode, Sara Tolaney, MD, of Dana-Farber Cancer Institute, discusses sequencing strategies after progression in HER2-positive metastatic breast cancer. She reviews current second-line standards, considerations for patients with brain metastases, and emerging therapies in the post–T-DXd setting.
Let us know what you thought of this week’s episode on Twitter: @physicianswkly
Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com!
